Sign In  |  Register  |  About San Rafael  |  Contact Us

San Rafael, CA
September 01, 2020 1:37pm
7-Day Forecast | Traffic
  • Search Hotels in San Rafael

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

Debiopharm announces poster presentations on data for their potentially best-in class compounds: Debio 0123, a brain-penetrant WEE1 inhibitor, and Debio 0432, a selective USP1 Inhibitor

Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced preclinical data releases for two of their compounds inhibiting the DNA-damage response (DDR) of cancer cells, including Debio 0123 [selective WEE1 inhibitor] and Debio 0432 [Selective USP1 Inhibitor] at the 2024 Annual American Association for Cancer Research (AACR) summit in San Diego, California.

Since 2017, Debiopharm has been growing its expertise in the DDR inhibitor field, firstly through its WEE1-inhibitor Debio 0123 and through the recently in-licensed asset, targeting USP1. These posters are proof of our commitment to stay at the forefront of DDR-inhibitor development and outsmart hard-to-treat cancers through synthetic lethality or other groundbreaking combinations.” - Angela Zubel, Chief Development Officer at Debiopharm

AACR 2024 Poster Presentations

Debiopharm compound

Title

Presenter

Mon, April 8th

Poster display: 9:00-12:30pm

Abstract #: CT064

Poster Section: 48

Poster Board #: 14

Debio 0123

Impact of food and high gastric pH on the bioavailability of the WEE1 inhibitor Debio 0123 assessed in a

Phase 1 dose escalation study

Anne Bellon, Clinical Pharmacology Lead

Mon, April 8th

Poster display: 1:30-5:00pm

Abstract #: 3370

Poster Section: 29

Poster Board #: 27

Debio 0123

Anti-tumor activity of Debio 0123 in combination with sacituzumab govitecan in preclinical models of breast cancer

Luke Piggott, Principal Scientist

Tue, April 9th

Poster display: 1:30-5:00pm

Abstract #: 6507

Poster Section: 46

Poster Board #: 24

Debio 0123

Simulation driven identification of combination for the WEE1 inhibitor Debio 0123 results in synergistic effect with cabozantinib validated in vivo

Luke Piggott, Principal Scientist

& Turbine AI

Wed, April 10th

Poster display: 9:00-12:30pm

Abstract #: 7145

Poster Section: 23

Poster Board #: 7

Debio 0432

Identification of Debio 0432 as a potent and selective USP1 inhibitor for cancer therapy

Noemie Luong, Associate Principal Scientist

 

About DNA-Damage Repair (DDR)

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debiopharm's WEE1 and USP1 inhibitors, are being tested in clinical and preclinical studies.

Debiopharm’s commitment to cancer patients

Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy, and then select large pharmaceutical commercialization partners to maximize patient access globally.

Visit us https://www.debiopharm.com/drug-development/

Follow us @DebiopharmNews

Contacts

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanRafael.com & California Media Partners, LLC. All rights reserved.